Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-021603
Filing Date
2022-11-03
Accepted
2022-11-03 09:14:44
Documents
55
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q mgta-20220930.htm   iXBRL 10-Q 2855141
2 EX-10.1 mgta-ex10_1.htm EX-10.1 147348
3 EX-31.1 mgta-ex31_1.htm EX-31.1 17899
4 EX-31.2 mgta-ex31_2.htm EX-31.2 18358
5 EX-32.1 mgta-ex32_1.htm EX-32.1 14155
  Complete submission text file 0000950170-22-021603.txt   7816311

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT mgta-20220930_def.xml EX-101.DEF 215988
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mgta-20220930_lab.xml EX-101.LAB 328568
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mgta-20220930.xsd EX-101.SCH 34823
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mgta-20220930_pre.xml EX-101.PRE 271065
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT mgta-20220930_cal.xml EX-101.CAL 42623
49 EXTRACTED XBRL INSTANCE DOCUMENT mgta-20220930_htm.xml XML 1186283
Mailing Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139
Business Address 100 TECHNOLOGY SQUARE 5TH FLOOR CAMBRIDGE MA 02139 857-201-2700
Magenta Therapeutics, Inc. (Filer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38541 | Film No.: 221356491
SIC: 2834 Pharmaceutical Preparations